Show simple item record

 
dc.contributorHospital Universitari de Girona Dr Josep Trueta
dc.contributor.authorMartínez-Horta, Saul
dc.contributor.authorBejr-Kasem, Helena
dc.contributor.authorHorta-Barba, Andrea
dc.contributor.authorPascual-Sedano, Berta
dc.contributor.authorSantos García, Diego
dc.contributor.authorde Deus Fonticoba, Teresa
dc.contributor.authorHernández Vara, Jorge
dc.contributor.authorSolano Vila, Berta
dc.contributor.authorde Fabregues-Boixar Nebot, Oriol
dc.date.accessioned2022-03-07T11:42:57Z
dc.date.available2022-03-07T11:42:57Z
dc.date.issued2021-12-08
dc.identifier.citationMartínez-Horta S, Bejr-Kasem H, Horta-Barba A, Pascual-Sedano B, Santos García D, de Deus-Fonticoba T, et al. Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. BMC Neurol. 2021 Dec 8;21(1):477.
dc.identifier.issn1471-2377
dc.identifier.urihttp://hdl.handle.net/11351/7121
dc.descriptionParkinson Disease; Cognition; Life Style
dc.description.abstractBackground: Identifying modifiable risk factors for cognitive impairment in the early stages of Parkinson's disease (PD) and estimating their impact on cognitive status may help prevent dementia (PDD) and the design of cognitive trials. Methods: Using a standard approach for the assessment of global cognition in PD and controlling for the effects of age, education and disease duration, we explored the associations between cognitive status, comorbidities, metabolic variables and lifestyle variables in 533 PD participants from the COPPADIS study. Results: Among the overall sample, 21% of participants were classified as PD-MCI (n = 114) and 4% as PDD (n = 26). The prevalence of hypertension, diabetes and dyslipidemia was significantly higher in cognitively impaired patients while no between-group differences were found for smoking, alcohol intake or use of supplementary vitamins. Better cognitive scores were significantly associated with regular physical exercise (p < 0.05) and cognitive stimulation (< 0.01). Cognitive performance was negatively associated with interleukin 2 (Il2) (p < 0.05), Il6 (p < 0.05), iron (p < 0.05), and homocysteine (p < 0.005) levels, and positively associated with vitamin B12 levels (p < 0.005). Conclusions: We extend previous findings regarding the positive and negative influence of various comorbidities and lifestyle factors on cognitive status in early PD patients, and reinforce the need to identify and treat potentially modifiable variables with the intention of exploring the possible improvement of the global cognitive status of patients with PD.
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.ispartofseriesBMC Neurology;21(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectParkinson, Malaltia de
dc.subjectCognició
dc.subject.meshCognition
dc.subject.meshLife Style
dc.subject.meshParkinson Disease
dc.titleIdentifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12883-021-02485-1
dc.subject.decsenfermedad de Parkinson
dc.subject.decscognición
dc.subject.decsestilo de vida
dc.relation.publishversionhttps://doi.org/10.1186/s12883-021-02485-1
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Martínez-Horta S, Bejr-Kasem H, Horta-Barba A, Pascual-Sedano B] Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain. Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. [Santos-García D] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [de Deus Fonticoba T] Complejo Hospitalario Universitario de Ferrol (CHUF), Ferrol, A Coruña, Spain. [Hernández Vara J, de Fábregues O ] Servei de Neurologia, Grup de Recerca en Malalties Neurodegeneratives, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Solano-Vila B] Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Hospital Santa Caterina, Institut d’Assistència Sanitària (IAS), Salt, Spain
dc.identifier.pmid34879838
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record